Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib

Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib
Condition:   Triple Negative Breast Cancer
Intervention:   Drug: Drug 1: LY3023414; Drug 2: Prexasertib
Sponsors:   Baylor Research Institute;   Eli Lilly and Company
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 26, 2019 / by / in
Comments